Goldman raised the price target for the BioNTech SE (NASDAQ:BNTX) stock to “a Neutral”. The rating was released on May 18, 2021. We previously noted in another research note published on May 11, 2021 by Bryan Garnier that downgraded the stock from a Buy to a Neutral with a price target of $206 for BNTX stock. The research report from BofA Securities has downgraded the stock from Buy to Neutral, with a price target set at $126. The stock was resumed by Berenberg, who disclosed in a research note on August 03, 2020, to Buy and set the price objective to $98. In their research brief published July 21, 2020, BofA Securities analysts upgraded the BioNTech SE stock from Neutral to Buy with a price target of $105.
Historical Earnings Surprises and Revenue Forecasts
Profit is the most critical financial performance measure. Every investor in a business is looking forward to the earnings report as stock price to increase when earnings exceed market expectations and progressively decrease when earnings do not meet expectations. The firm reported an earnings per share (EPS) of $5.38 during the last quarter as opposed to a consensus estimate of $3.78, which indicates the company beat its estimate by $1.6, which implies that the company surprised the market by 42.30%. It appears that the average earnings per share estimate for the current quarter (ending in Jun 2021) is $9.15. This is an average of 6 analysts’ earnings, where the high earnings per share estimate is $13.52 and the low earnings per share estimate is $4.76. According to 5 analyst estimates, an average revenue estimate of $3.88B is projected for the current quarter with a high revenue estimate of $5.16B and a low estimate of $2.88B.
The latest trade, Performances and Moving Averages give us the following Picture
The share price of BioNTech SE (NASDAQ:BNTX) raised 3.19% to close Friday’s market session at $204.00, higher as compared to yesterday’s close. The stock price fluctuated between $199.10 and $208.60 throughout the trading session with the volume trading being 2281220 shares, which represented a significant variation when compared to the three months average volume of 2.69 million shares. The firm’s stock price fluctuated 4.25% within the last five trades and 13.55% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price increased 94.36% in the last 6 months and 85.10% was added to its value over the previous 3 months. BNTX stock is trading at a margin of 6.24%, 31.82% and 87.27% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
As of the close of trading, BNTX deals in the Healthcare domain. The stock is trading -4.29 percent below its 52-week high and 338.24 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is 290.98. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does BioNTech SE’s Profitability and Valuation Ratios Tell Us About the Stock?
With regard to the profitability of the company, the operating margin is currently at 65.50 percent and the profit margin is 47.80 percent, and the company has reported a gross margin of 88.60 percent. The profit margin, also known as the revenue ratio or gross profit ratio, is an efficiency figure used to estimate the business’s profitability by comparing net income and sales. The higher the number, the more profits are generated for the company and vice versa.
The stock’s market cap achieved a total value of $51.29 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The price-to-earnings ratio for BioNTech SE (NASDAQ:BNTX) is 38.83. The price-to-earnings ratio is a method of assessing corporate values by comparing them to their per-share profit. Forward P/E stands at 6.65. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 16.76 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 16.10, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 1.18 percent of BioNTech SE shares are owned by insiders, and 13.50 percent are held by financial institutions.